Stress protein GDF-15 predicts five-year death risk in emergency chest pain patients
In 4,779 chest pain patients, GDF-15 was a weak heart attack test but a strong predictor of 5-year mortality, outperforming troponin and NT-proBNP.
Zusammenfassung
Growth differentiation factor-15 (GDF-15) is a stress-responsive blood protein linked to heart disease and wasting. Researchers measured it in 4,779 adults who came to emergency departments with acute chest pain, alongside the standard heart markers troponin T and NT-proBNP. GDF-15 was only modestly useful for spotting heart attacks (AUC 0.69), so it won't replace troponin for diagnosis. Its strength was predicting death from any cause: C-index 0.86 at 90 days and 0.84 at five years. That matched troponin and NT-proBNP in the short term and beat them over five years. Adding GDF-15 to a model already containing age, sex, risk factors, kidney function, troponin and NT-proBNP still improved risk discrimination. The findings suggest GDF-15 works better as a mortality-risk marker than a heart-attack test.
Detaillierte Zusammenfassung
Chest pain is among the most common reasons for emergency visits, and clinicians have excellent tools for deciding who is having a heart attack. They are much less equipped to identify who among all chest pain patients, whatever the final diagnosis, faces a high long-term risk of death. GDF-15 is a stress-induced circulating cytokine already known to predict mortality after established myocardial infarction and implicated in cachexia, which makes it a candidate for that broader role.
This international multicenter study (APACE investigators) enrolled 4,779 unselected adults presenting to emergency departments with acute chest pain. Median age was 61 and 33.2% were women. GDF-15, high-sensitivity cardiac troponin T and NT-proBNP were measured at presentation. Final diagnoses were adjudicated: 17.9% had myocardial infarction, 20.8% other cardiac conditions and 61.3% non-cardiac disorders. Endpoints were Non-ST-elevation MI at presentation and all-cause death at 90 days and 5 years.
For diagnosing MI, GDF-15 performed only modestly (AUC 0.69). For prognosis it performed very well. The C-index for all-cause death was 0.86 (95% CI 0.82-0.90) at 90 days and 0.84 (0.82-0.85) at 5 years. This was comparable to hs-cTnT and NT-proBNP at 90 days and higher at 5 years. Over follow-up, 557 deaths (12.1%) occurred. GDF-15 also added meaningful discrimination on top of a base model with age, sex, cardiovascular risk factors, creatinine, hs-cTnT and NT-proBNP.
The results suggest GDF-15 is better understood as a marker of overall biological vulnerability than of acute coronary injury. It could help flag patients who merit closer follow-up or more aggressive risk-factor management, whatever their chest pain diagnosis.
Caveats: only the abstract was available, so effect sizes for incremental value, calibration and cause-specific mortality are not reported here. The design is observational, and the findings show prediction, not that lowering GDF-15 improves outcomes. Several authors report industry ties, including diagnostic companies.
Wichtigste Erkenntnisse
- GDF-15 had only modest accuracy for diagnosing Non-ST-elevation MI at presentation (AUC 0.69), so it is not a substitute for troponin.
- GDF-15 predicted all-cause death very well at 90 days (C-index 0.86, 95% CI 0.82-0.90).
- At 5 years, GDF-15 reached a C-index of 0.84 (95% CI 0.82-0.85), higher than hs-cTnT and NT-proBNP.
- GDF-15 added meaningful prognostic discrimination beyond a base model including age, sex, risk factors, creatinine, hs-cTnT and NT-proBNP.
- Of 4,779 patients, 17.9% had MI and 61.3% had non-cardiac disorders, yet GDF-15 still stratified mortality risk.
Methodik
International multicenter diagnostic and prognostic cohort study (APACE) of 4,779 unselected emergency department patients with acute chest pain. GDF-15, hs-cTnT and NT-proBNP were measured at presentation, with final diagnoses adjudicated. Discrimination (AUC, C-index) was assessed for MI at presentation and for all-cause death at 90 days and 5 years, including incremental value over a rich base model.
Studienlimitierungen
This analysis is based on the abstract only, so incremental value metrics, calibration and cause-specific mortality are not available. The observational design shows prediction, not causation, and GDF-15 is elevated in many non-cardiac conditions, so it is nonspecific. Several authors disclose industry funding, including from diagnostic manufacturers, and external validation and clinical utility trials are still needed.
Hat dir diese Zusammenfassung gefallen?
Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.
E-Mail-Adresse zum Abonnieren eingeben:
